Oncocyte director Melinda Griffith to resign from board effective Jan 1, 2023

Insight Molecular Diagnostics Inc.

Resignation not due to any disagreement with company's operations, policies or practices.
Griffith chairs Nominating/Corporate Governance Committee and serves on Sciences and Technology Committee.
Effective date January 1, 2023.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Melinda Griffith

Director

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2023-01-01
Filed: November 23, 2022, 6:59 PM ET

On November 19, 2022, Melinda Griffith notified the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”) of her resignation from the Board, effective January 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Melinda Griffith resigned as Director at Insight Molecular Diagnostics Inc..

Action: resigned
Role: Director

Exact text from the filing

On November 19, 2022, Melinda Griffith notified the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”) of her resignation from the Board, effective January 1, 2023.

View on SEC.gov

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-033540

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.